Toussirot E, Wendling D
Department of Rheumatology, University Hospital J. Minjoz, Besançon, France.
Drugs. 1998 Aug;56(2):225-40. doi: 10.2165/00003495-199856020-00006.
Ankylosing spondylitis (AS) is a systemic inflammatory rheumatic disease involving spinal and sacroiliac joints. This condition is responsible for back pain, stiffness and discomfort. Several drugs are currently available in the management of AS, and may be divided into 3 groups. The first includes nonsteroidal anti-inflammatory drugs (NSAIDs), which are the main drug group used in AS because they reduce pain and stiffness in most patients. Several NSAIDs are available but phenylbutazone is considered the NSAID of choice in AS. However, other NSAIDs give similar beneficial results and the medication of preference in specific to each patient. All NSAIDs share common gastrointestinal toxicity, and they should be administered during periods of flare-up of the disease. The second drug group that has been used in the treatment of patients with AS comprises analgesics, muscle relaxants and low dose corticosteroids. They can be considered as adjuvant therapy. These drugs are helpful when NSAIDs are poorly tolerated or ineffective. Second-line treatments or disease modifying antirheumatic drugs (DMARDs) are included in the third group. These drugs are required in cases of longstanding severe or refractory AS. Sulfasalazine has proven to be effective in such cases, leading to improvement in clinical and laboratory indices of disease activity. Beneficial results are mainly evident in patients with AS who have peripheral disease involvement. Other medications (such as methotrexate or gold salts, for instance) require properly designed controlled studies to evaluate their effectiveness in the treatment of this disorder, while immunosuppressive agents have little to offer in the management of patients with AS and require further studies. Some specific clinical features are observed in AS: enthesopathy may be treated with local injection of corticosteroids; sacroiliac joint pain may be managed by corticosteroid injection performed under fluoroscopic control or guided by computed tomography. The management of patients with AS includes some other procedures such as patient education, rest, a programme of physical exercise and physiotherapy. In parallel with pharmacotherapy, these procedures are of great importance in reducing stiffness and spinal ankylosis, and thus improve the patient's quality of life.
强直性脊柱炎(AS)是一种累及脊柱和骶髂关节的全身性炎性风湿性疾病。该病会导致背痛、僵硬和不适。目前有几种药物可用于AS的治疗,可分为3类。第一类包括非甾体抗炎药(NSAIDs),这是AS治疗中使用的主要药物类别,因为它们能减轻大多数患者的疼痛和僵硬。有几种NSAIDs可供选择,但保泰松被认为是AS治疗中的首选NSAID。然而,其他NSAIDs也能产生类似的有益效果,具体的用药偏好因人而异。所有NSAIDs都有共同的胃肠道毒性,应在疾病发作期使用。用于治疗AS患者的第二类药物包括镇痛药、肌肉松弛剂和低剂量皮质类固醇。它们可被视为辅助治疗。当NSAIDs耐受性差或无效时,这些药物会有所帮助。第三类包括二线治疗药物或改善病情抗风湿药(DMARDs)。对于长期严重或难治性AS患者,需要使用这些药物。柳氮磺胺吡啶已被证明在这类病例中有效,可改善疾病活动的临床和实验室指标。有益效果主要在有外周疾病累及的AS患者中明显。其他药物(如甲氨蝶呤或金盐)需要经过精心设计的对照研究来评估其在治疗这种疾病中的有效性,而免疫抑制剂在AS患者的治疗中作用不大,需要进一步研究。AS患者存在一些特定的临床特征:附着点病可用局部注射皮质类固醇治疗;骶髂关节疼痛可通过在荧光镜控制下或计算机断层扫描引导下进行皮质类固醇注射来处理。AS患者的管理还包括一些其他措施,如患者教育、休息、体育锻炼计划和物理治疗。与药物治疗并行,这些措施对于减轻僵硬和脊柱强直非常重要,从而提高患者的生活质量。